

Atopic Dermatitis/Eczema at the 2017 SID Annual Meeting

Updated April 10 2017

(see full program details on [SID website](#) for most current info)

WEDNESDAY, April 26, 2017

8th Pan-Pacific Skin Barrier Symposium (PAPSBRS). A105-106.

9:00 am – 4:30 pm

1:15 pm **Plenary Talk #4**, Dr. E.H. Choi (Yonsei U Wonju), Stratum corneum acidification and its potential clinical application

1:45 pm **Plenary Talk #5**, Dr. K. Kabashima (Kyoto U), Cutaneous biological responses to external stimuli

2:15 pm Platform #8, Dr. S.J. Choe (Yonsei U Wonju), 11beta-hydroxysteroid dehydrogenase 1 expression in the skin might have a role in the occurrence of AD

2:30 pm Platform #9, Dr. M. Kishibe (Asahikawa Med U), Incomplete secretion of KLK7 and upregulated LEKTI are related to hyperkeratosis in stratum corneum in AD

2:45 pm Platform #10, Dr. A. Lowe (U Melbourne, AU), A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: PEBBLES pilot study

3:15 pm **Plenary Talk #6**, Dr. R. Gallo (UC San Diego), Links between barrier function, *S. aureus* colonization, and Th2 inflammation

Albert M. Kligman/Phillip Frost Leadership Lecture. Oregon Ballroom 201-202.

6:35 - 7:05 pm: Memory T Cells and Protective Immunity: Lessons from the Smallpox Vaccine. *Thomas S. Kupper, MD.*

THURSDAY, April 27, 2017

Pediatric Dermatology Research Alliance/Society for Pediatric Dermatology. Rooms A105 & A106

7:00–8:00 am: *Pediatric Dermatology at the SID.*

Selected ePoster Discussions I: Moderator Jonathan Silverberg. Exhibit Hall A Foyer

11:03 am #382 Adult-onset atopic dermatitis is associated with a distinct phenotype. *P. Vakharia, R. Chopra, R. Sacotti, N. Patel, S. Immaneni, R. Kantor, D. Hsu, J. Silverberg.*

Selected ePoster Discussions I: Moderator Delphine Lee. Exhibit Hall A Foyer

11:27 am #564: An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. *B. Ungar, S. Garcet, J. Gonzalez, J. Correa Da Rosa, N. Dhingra, A. Shermer, J. Krueger, M. Suarez-Farinas, E. Guttman-Yassky.*

Aclaris Sponsored Symposium: *You Don't Know JAK: Development of JAK inhibitors in Dermatology.* Oregon Ballroom 201-202.

12:00 pm Welcome and Introduction, *John Harris, MD/PhD*

12:05 pm Getting to know JAKs, *Paul Changelian, PhD*

12:15 pm JAKs be nimble: Building a Better Inhibitor, *Jon Jacobsen, PhD*

12:45 pm Scratch that Itch: JAK Inhibitors in Pruritus, *Brian S. Kim, MD/MTR*

1:05 pm JAK hammers: Topical Delivery for JAK Inhibitors, *Vijendra Nalamothu, PhD*

1:30 pm Panel Discussion and Q&A with Presenters

CONCURRENT MINI-SYMPOSIUM 3: *Interdisciplinary Spotlight: Frontiers in Atopic Dermatitis.* B113-116.

2:00 pm #640 Enhancement of Th2 polarization by Trim32 deficiency. *Y. Liu, Z. Wang, R. De La Torre, A. Barling, N. Hornick, J. Hanifin, E. Simpson and M. Kulesz-Martin.*

2:12 pm #624 PSM α as a key virulence in Staphylococcus aureus-induced skin inflammation through IL-36 and IL-1 release from keratinocytes. *S. Nakagawa, Y. Nakamura, G. Nunez and H. Matsue. Chiba*

2:24 pm #557 Microbiome controls mast cell differentiation in the skin. *Z. Wang, N. Mascarenhas, L. Eckmann, Y. Miyamoto, X. Sun, T. Kawakami and A. Di Nardo.*

2:36 pm #439 Mutations in the epidermal fatty acid and ceramide metabolic pathway reveal functions of the Corneocyte-Bound Lipid Envelope (CLE). *Elias, M. Man and D. Crumrine.*

2:48 pm #057 Regulation of lipid-specific T cell activation in human skin. *D. Lee, H. Jiang, W. Zeng, F. Kirscht, T. Kolster, S. Cremers and A. de Jong.*

3:00 pm #580 Neuronal IL-4R α and JAK1 signaling mediate chronic itch. *L. Oetjen, M. Mack, T. Whelan, C. Guo, L. Yang, S. Hamilton, P. Wang, H. Niu, J. Feng, A. Xu, S. Tripathi, J. Luo, J. Brestoff, A. Shaffer, C. Hsieh, R. Gereau, M. Miller, H. Hu, S. Davidson, Q. Liu and B. Kim.*

3:12 pm #526 Targeted sequencing of filaggrin identifies novel loss-of-function mutations in pediatric African American patients with severe atopic dermatitis. *M. Mathyer, A. Quiggle, S. Bayliss, C. Wong, S. Denil, J. Common and C. de Guzman Strong.*

3:24 pm #625 Differential diversity of staphylococcal strains shapes cutaneous response in atopic dermatitis. *A. Byrd, C. Deming, S. Cassidy, O. Harrison, W. Ng, S. Conlan, Y. Belkaid, J. Segre and H. Kong.*

3:36 pm #313 A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22/ILV-094 mAb. *E. Guttman-Yassky, S. Khattri, PM. Brunner, A. Neumann, K. Malik, J. Fuentes-Duculan, S. Garcet, M. Suarez-Farinas,*

M. Lebwohl and JG. Krueger.

3:48 pm #709 Nitric oxide-releasing topical therapeutic agent for atopic dermatitis. *K. McHale, J. Gil, S. Davis, S. Hollenbach and N. Stasko.*

4:00 pm #748 Tryptophan photoproduct 6-formylindolo[3,2-b]carbazole, FICZ, inhibits atopic dermatitis – A clue for photo-effectiveness to aryl hydrocarbon receptor. *M. Oda, H. Uchi, S. Morino-Koga and M. Furue.*

4:12 pm #155 Air pollution and incidence of eczema in elderly women. *W. Schnass, A. Hüls, A. Vierkötter, J. Xia, U. Krämer, J. Krutmann and T. Schikowski.*

CONCURRENT MINI-SYMPOSIUM 2: *Clinical Research: Pathophysiology and Therapeutics Including studies involving human tissue and human cells that furthers our understanding of skin disease.* Oregon Ballroom 203

3:24 pm #275 Oral vitamin D3 5000IU as an adjuvant in the treatment of atopic dermatitis: A randomized controlled trial. *K. Sanchez Armendariz, A. Garcia Gil, J. Contreras Ruiz, M. Karam Orante and J. Dominguez Cherit.*

IEC Councilor's meeting (IEC Councilors and Associates only). Rooms B117-119.

4:40 – 6:10 pm *TOPIC: Management of the Itch of AD.*

FRIDAY, April 28, 2017

Pediatric Dermatology Research Alliance/Society for Pediatric Dermatology. Rooms A105 & A106.

7:00–8:00 am *Pediatric Dermatology at the SID.*

PLENARY SESSION II: Oregon Ballroom 201-202.

8:36 am #197 Influence of FLG mutations and TSLP polymorphisms on atopic dermatitis onset age. *J. Wan, N. Mitra, OJ. Hoffstad and DJ. Margolis.*

Stephen Rothman Memorial Award. Oregon Ballroom 201-202.

9:00 – 9:15 am. Amy Paller, IEC President

Come See My Poster II: Oregon Ballroom 201-202

10:55 am #424 Sensitive skin is highly frequent in atopic dermatitis and correlates with disease severity markers but not necessarily with skin barrier assessments. *T. Yatagai, T. Shimauchi, H. Yamaguchi, J. Sakabe, M. Aoshima, S. Ikeya, K. Tatsuno, T. Fujiyama, T. Ito and Y. Tokura.*

International Eczema Council (IEC)

12:00-1:30 pm Oregon Ballroom 204

(Lunch served, free registration recommended at www.eczemacouncil.org).

12:00 pm Welcome/Overview of the IEC and Roadmap of AD at the SID *Amy Paller*

12:10-12:45 pm Abstract Presentations

#256: Increased interleukin-19 expression in cutaneous T-cell lymphoma as well as atopic dermatitis. *Oka Tomonori et al. Univ. of Tokyo, Tokyo, Japan*

#623: Cutaneous acquisition of Staphylococcus quorum-sensing agr mutations protects against atopic dermatitis development. *Yuumi Nakamura et al., Chiba Univ., Chiba, Japan*

#642: The serum proteomic signature of pediatric AD suggests early Th2/Th17 skewing and an inverse correlation of disease severity with Th1 markers. *Patrick Brunner et al. Rockefeller Univ., New York, NY, USA*

12:45 pm **Special Presentation: The precise control of skin barrier homeostasis** *Masayuki Amagai, Keio University, Tokyo, Japan*

1:10-1:30 pm Abstract Presentations

#296: Bleach baths promote early induction of inflammatory pathway genes with no effect on skin bacterial dysbiosis in AD subjects. *Sara Knowlden et al., Univ. of Rochester, Rochester, NY, USA*

#251: Treatment interruption did not impact efficacy or long-term safety of dupilumab: A phase 3 open-label trial. *Lisa Beck et al. Univ. of Rochester, Rochester, NY, USA*

Selected ePoster Discussions II: Moderator: Robert Dellavalle. Exhibit Hall A Foyer

12:48 pm #220 Predictors and cost of hospitalization for atopic dermatitis in US adults and children. *S. Narla, D. Hsu, J. Thyssen, J. Silverberg.*

Selected ePoster Discussions II: Moderator: Theodora Mauro. Exhibit Hall A Foyer

12:00 pm #636 Commensal skin bacteria inhibit the capacity of Staphylococcus aureus to induce epidermal serine protease activity in atopic dermatitis. *M. Williams, T. Nakatsuji, R. Gallo.*

12:42 pm #438 Activation of protease-activated receptor 2 leads to impairment of keratinocyte differentiation and tight junction integrity. *M. Henehan; P. Nadeau; A. DeBenedetto.*

12:54 pm #403 S. aureus colonization is associated with dysregulation of lipid-related genes in the nonlesional skin of AD subjects. *C. Kwon, T. Yoshida, S. Knowlden, A. DeBenedetto, J. Myers, D. Leung, S. Gill, J. Thakar, L. Beck.*

American Dermato-Epidemiology Network (ADEN) Symposium. B117-119.

1:00 pm #243 Real world systemic corticosteroid (SCS) utilization patterns and costs in adult patients with atopic dermatitis. *A. Armstrong, W. Wei, R. Miao, M. Patel, A. Huang, L. Wand, J. Chao.*

CONCURRENT MINI-SYMPOSIUM 6: *Clinical Research: Patient Outcomes Research*
Includes meta-analysis of interventional trials, and patient outcomes research. Oregon Ballroom 204

2:48 pm #334 Direct-access online care for the management of atopic dermatitis: A randomized controlled clinical trial examining patient quality of life. H. Kornmehl, S. Singh, M. Johnson and A. Armstrong.

3:00 pm #383 Establishing severity strata for 5 different patient-reported outcomes in adults with atopic dermatitis. R. Sacotte, P. Vakharia, R. Chopra, N. Patel, S. Immaneni, T. White, R. Kantor, D. Hsu, E. Simpson and J. Silverberg.

CONCURRENT MINI-SYMPOSIUM 7: *Genetic Disease, Gene Regulation and Gene Therapy Studies on cutaneous gene expression and genetic diseases including gene therapy.* B113-116

2:24 pm #495 Ichthyosis molecular fingerprinting shows profound Th17-skewing and a unique barrier gene expression pattern. *H. He, T. Huynh, E. Ibler, K. Malik, G. Tran, H. Esaki, J.G. Krueger, AS. Paller and E. Guttman-Yassky.*

3:48 pm #492 SNPs within the MHC associated with atopic dermatitis are located within miRNA sequences. *P. Clark, N. Chitnis, M. Kamoun, B. Johnson, DJ. Margolis and D. Monos.*

CONCURRENT MINI-SYMPOSIUM 8: *Innate Immunity, Microbiology, Inflammation Studies of cells, receptors and effector molecules of the innate immune response; studies on skin microbes and infectious processes of the skin.* Oregon Ballroom 203

3:12 pm #643 An atopic dermatitis-like flare is mediated by dysbiosis and release of nuclear IL 1 α from keratinocytes. *N. Archer, S. Lee, R. Ortines, Y. Wang, H. Liu, R. Miller, C. Dillen, M. Marchitto, A. Ashbaugh, A. Uppal, S. Cai, N. Malhotra, M. Oyoshi, R. Geha and L. Miller.*

IEC Industry Liaison Meeting (invite only–email mjung@eczemacouncil.org)

4:45-5:30 pm *IEC Update. Room B11*

Introducing a New Topical Prescription Treatment Option for Atopic Dermatitis (Pfizer): Oregon Ballroom 201-202

5:00 pm – 5:45 pm. Lawrence Eichenfield, MD Professor of Dermatology and Pediatrics

National Eczema Association Reception

6:00-7:00 pm, A105-106

SATURDAY, April 29, 2017

Come See My Poster III: Oregon Ballroom 201-202

10:03 am #421 Elevated serum IgE level, but not TARC and LDH, may reflect the impairment of stratum corneum barrier function in healthy individuals; Results of cross-sectional study of 1141 Japanese healthy individuals. *E. Akasaka, K. Hara, M. Takahashi, T.*

Fukui, A. Korekawa, H. Nakano, I. Takahashi, S. Nakaji and D. Sawamura.

Selected ePoster Discussions III: Moderator: Masayuki Amagai. Exhibit Hall A Foyer
10:45am #001 Malat1 drives differentiation of memory CD8+ T cells. *N. Carter et al.*

CONCURRENT MINI-SYMPOSIUM 12: Clinical Research: Epidemiology of Skin Diseases
Oregon Ballroom 203

12:42 pm #164 Changes in the geographic distribution of atopic dermatitis on the body with age. *TT. Schwartz, DJ. Margolis and K. Abuabara.*

12:54 pm #221 Does atopic dermatitis remain a disease of the advantaged in adulthood? A national birth cohort study. *K. Abuabara, LL. Kohn and SM. Langan.*

1:06 pm #198 Black children less likely to receive outpatient care for eczema than whites, but show signs of more severe disease: A cross-sectional analysis of the medical expenditure panel surveys. *DB. Shin, AH. Fischer, DJ. Margolis and J. Takeshita.*

1:18 pm #204 A real-world study evaluating adequacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST): Baseline treatment patterns and unmet needs assessment. *W. Wei, E. Ghorayeb, ML. Andria, V. Walker, J. Chao, J. Schnitzer, M. Kennedy, Z. Chen, A. Belland, J. White and JI. Silverberg.*

CONCURRENT MINI-SYMPOSIUM 15: Pharmacology and Drug Development
Basic and preclinical studies aimed at developing therapeutics, elucidating their mechanisms of action, and identifying biomarkers of drug activity. 105-106

12:54 pm #718 Allergen-loaded microneedle patches efficiently induce Treg cells in atopic dermatitis. *C. Park, S. Kim, JU. Shin, J. Kim, Z. Sun and K. Lee.*

POSTERS NOT BEING PRESENTED ORALLY

#038 Hyaluronan oligosaccharides induce suppressive effect to chronic allergic dermatitis. *J. Muto et al.*

#058 Non-lesional atopic dermatitis skin shares similar T cell clones with lesional tissues. *Brunner P, R. Emerson et al.*

#073 Th17 and Th22 polarization in ichthyosis blood correlates with disease severity and highlights its systemic nature. *T. Czarnowicki et al.*

#080 IL-9 promotes Th responses in epicutaneous sensitization with protein antigens. *L. Wang et al.*

#082 Systemic atopic dermatitis has different immune signatures. *J. Lee et al.*

#153 Topical corticosteroid phobia and fear in atopic dermatitis: A systematic review. *A. Li et al.*

#173 Systematic review of atopic dermatitis disease definitions in routinely-collected health data. *M. Dizon et al.*

#195 The burden of childhood atopic dermatitis in U.S. primary care settings. *J. Al-naqeeb et al.*

#206 Racial/ethnic differences in healthcare utilization and school attendance among children with atopic dermatitis in the Pediatric Eczema Elective Registry. *J. Takeshita et al.*

#223 Atopic dermatitis is associated with increased risk of serious infections in US children and adults. *S. Narla et al.*

#228 The prevalence of eczema beyond childhood: A systematic review and meta-analysis of longitudinal studies. *A. Yu et al.*

#232 New nonsynonymous variants of SPINK5 gene in Japanese atopic dermatitis patients. *S. Morizane et al.*

#244 Risk of contraindication and drug-drug interaction (DDI) with use of systemic immunosuppressants (IMMs) in adult patients with atopic dermatitis (AD). *A. Armstrong et al.*

#263 Increased interleukin-36 γ expression in skin and sera of patients with atopic dermatitis and cutaneous T-cell lymphoma. *S. Otake et al.*

#282 Risk of skin infections with dupilumab for atopic dermatitis: systematic review and meta-analysis of randomized controlled trials. *A. Drucker et al.*

#298 RNA-seq profiling highlights the robust inflammation and Th17-skewing of the non-lesional Asian atopic dermatitis phenotype. *H. Wen et al.*

#304 Collagent tripeptide may modulate inflammation in atopic dermatitis. *A. Hakuta et al.*

#385 Standardizing the diagnostic criteria used for atopic dermatitis: a systematic review. *P. Vakharia et al.*

#386 A systematic review of inclusion criteria for clinical trials of atopic dermatitis. *R. Chopra et al.*

#394 Comparison of EASI and objective-SCORAD assessments in adult atopic dermatitis. *R. Chopra et al.*

#409 Profiling of epidermal lipids to identify potential biomarkers of atopic dermatitis. *J. Franco et al.*

#411 Novel filaggrin gene polymorphisms in atopic dermatitis. *A. Huang et al.*

#415 Air exposure and dehydration down-regulates EGFR and Aquaporin 3 in cultured human skin keratinocytes. *W Zhang et al.*

#417 A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitisation: The PEBBLES pilot study. *A. Lowe et al.*

#420 The effects of bathing, showering and petrolatum on skin barrier function. *E. Bolton et al.*

#429 The ratio of sphingosine to sphinganine in the stratum corneum determines lipid lamellar structure packing. *Y. Obata et al.*

#430 IFN- γ may disrupt skin barrier function through reduction of long-chain fatty acid ceramides in mite-induced dermatitis. *H. Kano et al.*

#437 A suitable Raman microspectroscopy data processing: the key to understand atopic dermatitis in vivo at the molecular level. *L. Verzeaux et al.*

#444 Reactive oxygen species induce Th2 allergic inflammation in the skin by activating PI3K-HIF- α pathway. *J. Choi et al.*

#446 Early atopic dermatitis biological analysis. *G. Bellemere et al.*

#533 Array-based sequencing of filaggrin gene for comprehensive detection of disease-associated variants. *C. Wong et al.*

#583 Atopic keratoconjunctivitis spontaneously develop in a mouse model of atopic dermatitis expressing the mouse interleukin-33 gene driven by a keratin 14 promoter. *Y. Imai et al.*

#587 Identification of IL-4 regulated microRNAs in primary keratinocytes. *L. Bao et al.*

#593 Staphylococcal enterotoxin B modifies ovalbumin-induced innate immune responses and skin inflammation in a murine model of atopic dermatitis. *S. Fassbender et al.*

#598 Increased expression of TRPV3 and TRPV4 channel in keratinocytes under Th2 inflammation. *H. Ko et al.*

#617 Basophils release amphiregulin and may contribute to murine models of prurigo reaction and MC903-induced atopic dermatitis-like skin inflammation. *T. Hashimoto et al.*

#620 Possible involvement of interleukin-33 and basophils in the pathophysiology of human atopic dermatitis via ST2 receptor. *Y. Nonomura et al.*

#656 Changes of lesional and non-lesional skin microbiome in the treatment course of atopic dermatitis. *J. Na et al.*

#676 Fluorescence lifetime imaging microscopy (FLIM) as a novel method to assess skin residency of a fluorescent compound: experience with GSK2894512. *A. Alex et al.*

#691 The effects of RVT-501 on DNCB-induced atopic dermatitis in NC/Nga mice. *R. Roeloffs et al.*

#693 Dust mite potently activates Th17/Th22 pathways and models multiple inflammatory skin conditions in humans. *K. Malik et al.*

#695 Topical application of KPI-150, a potent inhibitor of Kv1.3 channels on effector memory T cells, demonstrates preclinical efficacy in atopic dermatitis model. *C. Olsen et al.*

#697 Atopic dermatitis treatment: New insight through 3D in vitro models. *P. Rouaud-Tingue et al.*

#702 Prescriptions for atopic dermatitis: Oral corticosteroids remain commonplace. *T. Alexander et al.*

#708 SIG-1451: A topical anti-inflammatory new chemical entity for atopic dermatitis (AD). *J. Fernandez et al.*

#898 Homeostatic activation of epidermal HSD11b1 affects skin innervation and non-histaminergic itch. *A. Matsumoto et al.*